GT
RGNX icon

Glenmede Trust’s Regenxbio RGNX Stock Holding History

Glenmede Trust’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-436
Closed -$11K – 2024
2020
Q3 		$11K Sell
436
-250
-36% -$8.15K ﹤0.01% 1850
2020
Q2 		$24K Buy
686
+141
+26% +$5.26K ﹤0.01% 1525
2020
Q1 		$21K Hold
545
– – ﹤0.01% 2078
2019
Q4 		$21K Buy
545
+332
+156% +$13.1K ﹤0.01% 2078
2019
Q3 		$7K Sell
213
-20
-9% -$810 ﹤0.01% 2511
2019
Q2 		$11K Hold
233
– – ﹤0.01% 2335
2019
Q1 		$12K Hold
233
– – ﹤0.01% 2295
2018
Q4 		$9K Buy
+233
New +$13.7K ﹤0.01% 2324

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Korea Investment Corp
Korea Investment Corp Seoul, South Korea $52.7B AUM 42.7% 1-Year Est. Return

Glenmede Trust's RGNX Position: Q4 2020 in Review

Glenmede Trust sold out of Regenxbio (RGNX) in Q4 2020, closing a stake of 436 shares — an estimated $11K sold.

Glenmede Trust first reported a position in RGNX in Q4 2018 and held it in 8 quarters. The position peaked at $24K in Q2 2020. 187 funds tracked by Wall St. Rank hold RGNX as of Q4 2020.

  • Glenmede Trust reported no remaining Regenxbio position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 436 Regenxbio shares in Q4 2020, an estimated $11K.
  • Glenmede Trust first reported a position in Regenxbio in Q4 2018 and held it in 8 quarters.
  • Glenmede Trust's Regenxbio position peaked at $24K in Q2 2020.
  • 187 funds tracked by Wall St. Rank held Regenxbio as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.